Ignite Creation Date:
2024-05-06 @ 3:52 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04783207
Status:
COMPLETED
Last Update Posted:
2023-08-31
First Post:
2021-02-05
Brief Title:
Effects of Mitopure Urolithin A on Skeletal Muscle Function Iron Metabolism and Endurance Performance
Sponsor:
Amazentis SA
Organization:
Amazentis SA
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Effects of Mitopure Urolithin A on Skeletal Muscle Function Iron Metabolism and Endurance Performance in Athletes
Status:
COMPLETED
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ENDURO
Brief Summary:
This is a randomized double-blind placebo-controlled study enrolling 36 16 Elite and 20 Sub-Elite trained endurance runners 18 placebo and 18 Mitopure intervention who are 18-40 years of age Mitopure or Placebo supplement will be given as a daily oral dose for 4-weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None